Petryka, Robert
3 papers on CoChat
Most cited papers
- Verified
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 3,163
- Verified
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 638
- Verified
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet
Inflammatory Bowel DiseaseRheumatoid Arthritis Research and Therapies
Cited by 439
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free